Review



exosome based therapy  (Exosome Diagnostics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Exosome Diagnostics exosome based therapy
    ( a ) Activated immune cells: TLR3 agonists reverse tumor-induced immune tolerance. Cell-free vaccines composed of tumor-derived exosomes can elicit robust and durable tumor antigen-specific T cell responses. Exosome-mimicking liposomal formulations carrying miR-155-5p, as well as engineered hexamer ExoBlock with six high-affinity PS-binding sites, can activate CD8⁺ T cells, promote Treg proliferation and upregulate PD-L1, thereby markedly improving the efficacy of checkpoint blockade therapy. ( b ) Chemoresistance sensitization: miR497/TP-HENPs, hybrid nanoparticles integrating liposomes and exosomes and co-loaded with TP and miR497, specifically block the PI3K/AKT/mTOR pathway and effectively reverse chemoresistance in ovarian cancer. Dendritic cell-derived exosomes expressing RGD-Lamp2b fusion proteins can deliver miR-484 in a targeted manner to normalize tumor vasculature and sensitize cancer cells to chemotherapy. ( c ) Engineered exosomes: Exosomes loaded with mangiferin and curcumin, as well as exosomes electroporated with plasmids encoding Cas9 and PARP-1 sgRNA, efficiently induce apoptosis in ovarian cancer cells. Exosomes carrying ephrin-B2 ligands bind to LAMP-2b and target ephrin-B4 on ovarian cancer cell surfaces, which greatly reduces systemic toxicities. RGD-modified exosomes possess enhanced cellular penetration ability. Their highly expressed miR-92b-3p targets SOX4 to suppress tumor growth and angiogenesis; combined with apatinib, they exert a potent synergistic anti-tumor effect via anti-angiogenesis. M-Trap is <t>an</t> <t>exosome-based</t> tumor capture technology that immobilizes exosomes purified from ascites of ovarian cancer patients onto 3D polystyrene/polycaprolactone scaffolds. It mimics the extracellular microenvironment to compete for implantation sites and inhibit peritoneal metastasis, which has been validated in relevant models.
    Exosome Based Therapy, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exosome+based+therapy/pmc13282986-398-0-0?v=Exosome+Diagnostics
    Average 86 stars, based on 1 article reviews
    exosome based therapy - by Bioz Stars, 2026-07
    86/100 stars

    Images

    1) Product Images from "Exosomes in Ovarian Cancer: Promoters, Biomarkers, and Therapeutic Targets"

    Article Title: Exosomes in Ovarian Cancer: Promoters, Biomarkers, and Therapeutic Targets

    Journal: International Journal of Nanomedicine

    doi: 10.2147/IJN.S606735

    ( a ) Activated immune cells: TLR3 agonists reverse tumor-induced immune tolerance. Cell-free vaccines composed of tumor-derived exosomes can elicit robust and durable tumor antigen-specific T cell responses. Exosome-mimicking liposomal formulations carrying miR-155-5p, as well as engineered hexamer ExoBlock with six high-affinity PS-binding sites, can activate CD8⁺ T cells, promote Treg proliferation and upregulate PD-L1, thereby markedly improving the efficacy of checkpoint blockade therapy. ( b ) Chemoresistance sensitization: miR497/TP-HENPs, hybrid nanoparticles integrating liposomes and exosomes and co-loaded with TP and miR497, specifically block the PI3K/AKT/mTOR pathway and effectively reverse chemoresistance in ovarian cancer. Dendritic cell-derived exosomes expressing RGD-Lamp2b fusion proteins can deliver miR-484 in a targeted manner to normalize tumor vasculature and sensitize cancer cells to chemotherapy. ( c ) Engineered exosomes: Exosomes loaded with mangiferin and curcumin, as well as exosomes electroporated with plasmids encoding Cas9 and PARP-1 sgRNA, efficiently induce apoptosis in ovarian cancer cells. Exosomes carrying ephrin-B2 ligands bind to LAMP-2b and target ephrin-B4 on ovarian cancer cell surfaces, which greatly reduces systemic toxicities. RGD-modified exosomes possess enhanced cellular penetration ability. Their highly expressed miR-92b-3p targets SOX4 to suppress tumor growth and angiogenesis; combined with apatinib, they exert a potent synergistic anti-tumor effect via anti-angiogenesis. M-Trap is an exosome-based tumor capture technology that immobilizes exosomes purified from ascites of ovarian cancer patients onto 3D polystyrene/polycaprolactone scaffolds. It mimics the extracellular microenvironment to compete for implantation sites and inhibit peritoneal metastasis, which has been validated in relevant models.
    Figure Legend Snippet: ( a ) Activated immune cells: TLR3 agonists reverse tumor-induced immune tolerance. Cell-free vaccines composed of tumor-derived exosomes can elicit robust and durable tumor antigen-specific T cell responses. Exosome-mimicking liposomal formulations carrying miR-155-5p, as well as engineered hexamer ExoBlock with six high-affinity PS-binding sites, can activate CD8⁺ T cells, promote Treg proliferation and upregulate PD-L1, thereby markedly improving the efficacy of checkpoint blockade therapy. ( b ) Chemoresistance sensitization: miR497/TP-HENPs, hybrid nanoparticles integrating liposomes and exosomes and co-loaded with TP and miR497, specifically block the PI3K/AKT/mTOR pathway and effectively reverse chemoresistance in ovarian cancer. Dendritic cell-derived exosomes expressing RGD-Lamp2b fusion proteins can deliver miR-484 in a targeted manner to normalize tumor vasculature and sensitize cancer cells to chemotherapy. ( c ) Engineered exosomes: Exosomes loaded with mangiferin and curcumin, as well as exosomes electroporated with plasmids encoding Cas9 and PARP-1 sgRNA, efficiently induce apoptosis in ovarian cancer cells. Exosomes carrying ephrin-B2 ligands bind to LAMP-2b and target ephrin-B4 on ovarian cancer cell surfaces, which greatly reduces systemic toxicities. RGD-modified exosomes possess enhanced cellular penetration ability. Their highly expressed miR-92b-3p targets SOX4 to suppress tumor growth and angiogenesis; combined with apatinib, they exert a potent synergistic anti-tumor effect via anti-angiogenesis. M-Trap is an exosome-based tumor capture technology that immobilizes exosomes purified from ascites of ovarian cancer patients onto 3D polystyrene/polycaprolactone scaffolds. It mimics the extracellular microenvironment to compete for implantation sites and inhibit peritoneal metastasis, which has been validated in relevant models.

    Techniques Used: Vaccines, Derivative Assay, Binding Assay, Liposomes, Blocking Assay, Expressing, Modification, Purification



    Similar Products

    exosome based therapy  (Exosome Diagnostics)
    86
    Exosome Diagnostics exosome based therapy
    ( a ) Activated immune cells: TLR3 agonists reverse tumor-induced immune tolerance. Cell-free vaccines composed of tumor-derived exosomes can elicit robust and durable tumor antigen-specific T cell responses. Exosome-mimicking liposomal formulations carrying miR-155-5p, as well as engineered hexamer ExoBlock with six high-affinity PS-binding sites, can activate CD8⁺ T cells, promote Treg proliferation and upregulate PD-L1, thereby markedly improving the efficacy of checkpoint blockade therapy. ( b ) Chemoresistance sensitization: miR497/TP-HENPs, hybrid nanoparticles integrating liposomes and exosomes and co-loaded with TP and miR497, specifically block the PI3K/AKT/mTOR pathway and effectively reverse chemoresistance in ovarian cancer. Dendritic cell-derived exosomes expressing RGD-Lamp2b fusion proteins can deliver miR-484 in a targeted manner to normalize tumor vasculature and sensitize cancer cells to chemotherapy. ( c ) Engineered exosomes: Exosomes loaded with mangiferin and curcumin, as well as exosomes electroporated with plasmids encoding Cas9 and PARP-1 sgRNA, efficiently induce apoptosis in ovarian cancer cells. Exosomes carrying ephrin-B2 ligands bind to LAMP-2b and target ephrin-B4 on ovarian cancer cell surfaces, which greatly reduces systemic toxicities. RGD-modified exosomes possess enhanced cellular penetration ability. Their highly expressed miR-92b-3p targets SOX4 to suppress tumor growth and angiogenesis; combined with apatinib, they exert a potent synergistic anti-tumor effect via anti-angiogenesis. M-Trap is <t>an</t> <t>exosome-based</t> tumor capture technology that immobilizes exosomes purified from ascites of ovarian cancer patients onto 3D polystyrene/polycaprolactone scaffolds. It mimics the extracellular microenvironment to compete for implantation sites and inhibit peritoneal metastasis, which has been validated in relevant models.
    Exosome Based Therapy, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exosome+based+therapy/pmc13282986-398-0-0?v=Exosome+Diagnostics
    Average 86 stars, based on 1 article reviews
    exosome based therapy - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    engineered exosome based therapies  (Exosome Diagnostics)
    86
    Exosome Diagnostics engineered exosome based therapies
    ( a ) Activated immune cells: TLR3 agonists reverse tumor-induced immune tolerance. Cell-free vaccines composed of tumor-derived exosomes can elicit robust and durable tumor antigen-specific T cell responses. Exosome-mimicking liposomal formulations carrying miR-155-5p, as well as engineered hexamer ExoBlock with six high-affinity PS-binding sites, can activate CD8⁺ T cells, promote Treg proliferation and upregulate PD-L1, thereby markedly improving the efficacy of checkpoint blockade therapy. ( b ) Chemoresistance sensitization: miR497/TP-HENPs, hybrid nanoparticles integrating liposomes and exosomes and co-loaded with TP and miR497, specifically block the PI3K/AKT/mTOR pathway and effectively reverse chemoresistance in ovarian cancer. Dendritic cell-derived exosomes expressing RGD-Lamp2b fusion proteins can deliver miR-484 in a targeted manner to normalize tumor vasculature and sensitize cancer cells to chemotherapy. ( c ) Engineered exosomes: Exosomes loaded with mangiferin and curcumin, as well as exosomes electroporated with plasmids encoding Cas9 and PARP-1 sgRNA, efficiently induce apoptosis in ovarian cancer cells. Exosomes carrying ephrin-B2 ligands bind to LAMP-2b and target ephrin-B4 on ovarian cancer cell surfaces, which greatly reduces systemic toxicities. RGD-modified exosomes possess enhanced cellular penetration ability. Their highly expressed miR-92b-3p targets SOX4 to suppress tumor growth and angiogenesis; combined with apatinib, they exert a potent synergistic anti-tumor effect via anti-angiogenesis. M-Trap is <t>an</t> <t>exosome-based</t> tumor capture technology that immobilizes exosomes purified from ascites of ovarian cancer patients onto 3D polystyrene/polycaprolactone scaffolds. It mimics the extracellular microenvironment to compete for implantation sites and inhibit peritoneal metastasis, which has been validated in relevant models.
    Engineered Exosome Based Therapies, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exosome+based+therapy/pm42261618-334-16-17?v=Exosome+Diagnostics
    Average 86 stars, based on 1 article reviews
    engineered exosome based therapies - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    exosome based treatments  (Exosome Diagnostics)
    86
    Exosome Diagnostics exosome based treatments
    ( a ) Activated immune cells: TLR3 agonists reverse tumor-induced immune tolerance. Cell-free vaccines composed of tumor-derived exosomes can elicit robust and durable tumor antigen-specific T cell responses. Exosome-mimicking liposomal formulations carrying miR-155-5p, as well as engineered hexamer ExoBlock with six high-affinity PS-binding sites, can activate CD8⁺ T cells, promote Treg proliferation and upregulate PD-L1, thereby markedly improving the efficacy of checkpoint blockade therapy. ( b ) Chemoresistance sensitization: miR497/TP-HENPs, hybrid nanoparticles integrating liposomes and exosomes and co-loaded with TP and miR497, specifically block the PI3K/AKT/mTOR pathway and effectively reverse chemoresistance in ovarian cancer. Dendritic cell-derived exosomes expressing RGD-Lamp2b fusion proteins can deliver miR-484 in a targeted manner to normalize tumor vasculature and sensitize cancer cells to chemotherapy. ( c ) Engineered exosomes: Exosomes loaded with mangiferin and curcumin, as well as exosomes electroporated with plasmids encoding Cas9 and PARP-1 sgRNA, efficiently induce apoptosis in ovarian cancer cells. Exosomes carrying ephrin-B2 ligands bind to LAMP-2b and target ephrin-B4 on ovarian cancer cell surfaces, which greatly reduces systemic toxicities. RGD-modified exosomes possess enhanced cellular penetration ability. Their highly expressed miR-92b-3p targets SOX4 to suppress tumor growth and angiogenesis; combined with apatinib, they exert a potent synergistic anti-tumor effect via anti-angiogenesis. M-Trap is <t>an</t> <t>exosome-based</t> tumor capture technology that immobilizes exosomes purified from ascites of ovarian cancer patients onto 3D polystyrene/polycaprolactone scaffolds. It mimics the extracellular microenvironment to compete for implantation sites and inhibit peritoneal metastasis, which has been validated in relevant models.
    Exosome Based Treatments, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exosome+based+therapy/pm42243420-122-0-0?v=Exosome+Diagnostics
    Average 86 stars, based on 1 article reviews
    exosome based treatments - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    exosome based therapies  (Exosome Diagnostics)
    86
    Exosome Diagnostics exosome based therapies
    ( a ) Activated immune cells: TLR3 agonists reverse tumor-induced immune tolerance. Cell-free vaccines composed of tumor-derived exosomes can elicit robust and durable tumor antigen-specific T cell responses. Exosome-mimicking liposomal formulations carrying miR-155-5p, as well as engineered hexamer ExoBlock with six high-affinity PS-binding sites, can activate CD8⁺ T cells, promote Treg proliferation and upregulate PD-L1, thereby markedly improving the efficacy of checkpoint blockade therapy. ( b ) Chemoresistance sensitization: miR497/TP-HENPs, hybrid nanoparticles integrating liposomes and exosomes and co-loaded with TP and miR497, specifically block the PI3K/AKT/mTOR pathway and effectively reverse chemoresistance in ovarian cancer. Dendritic cell-derived exosomes expressing RGD-Lamp2b fusion proteins can deliver miR-484 in a targeted manner to normalize tumor vasculature and sensitize cancer cells to chemotherapy. ( c ) Engineered exosomes: Exosomes loaded with mangiferin and curcumin, as well as exosomes electroporated with plasmids encoding Cas9 and PARP-1 sgRNA, efficiently induce apoptosis in ovarian cancer cells. Exosomes carrying ephrin-B2 ligands bind to LAMP-2b and target ephrin-B4 on ovarian cancer cell surfaces, which greatly reduces systemic toxicities. RGD-modified exosomes possess enhanced cellular penetration ability. Their highly expressed miR-92b-3p targets SOX4 to suppress tumor growth and angiogenesis; combined with apatinib, they exert a potent synergistic anti-tumor effect via anti-angiogenesis. M-Trap is <t>an</t> <t>exosome-based</t> tumor capture technology that immobilizes exosomes purified from ascites of ovarian cancer patients onto 3D polystyrene/polycaprolactone scaffolds. It mimics the extracellular microenvironment to compete for implantation sites and inhibit peritoneal metastasis, which has been validated in relevant models.
    Exosome Based Therapies, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exosome+based+therapy/pm42243142-0-0-0?v=Exosome+Diagnostics
    Average 86 stars, based on 1 article reviews
    exosome based therapies - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    ( a ) Activated immune cells: TLR3 agonists reverse tumor-induced immune tolerance. Cell-free vaccines composed of tumor-derived exosomes can elicit robust and durable tumor antigen-specific T cell responses. Exosome-mimicking liposomal formulations carrying miR-155-5p, as well as engineered hexamer ExoBlock with six high-affinity PS-binding sites, can activate CD8⁺ T cells, promote Treg proliferation and upregulate PD-L1, thereby markedly improving the efficacy of checkpoint blockade therapy. ( b ) Chemoresistance sensitization: miR497/TP-HENPs, hybrid nanoparticles integrating liposomes and exosomes and co-loaded with TP and miR497, specifically block the PI3K/AKT/mTOR pathway and effectively reverse chemoresistance in ovarian cancer. Dendritic cell-derived exosomes expressing RGD-Lamp2b fusion proteins can deliver miR-484 in a targeted manner to normalize tumor vasculature and sensitize cancer cells to chemotherapy. ( c ) Engineered exosomes: Exosomes loaded with mangiferin and curcumin, as well as exosomes electroporated with plasmids encoding Cas9 and PARP-1 sgRNA, efficiently induce apoptosis in ovarian cancer cells. Exosomes carrying ephrin-B2 ligands bind to LAMP-2b and target ephrin-B4 on ovarian cancer cell surfaces, which greatly reduces systemic toxicities. RGD-modified exosomes possess enhanced cellular penetration ability. Their highly expressed miR-92b-3p targets SOX4 to suppress tumor growth and angiogenesis; combined with apatinib, they exert a potent synergistic anti-tumor effect via anti-angiogenesis. M-Trap is an exosome-based tumor capture technology that immobilizes exosomes purified from ascites of ovarian cancer patients onto 3D polystyrene/polycaprolactone scaffolds. It mimics the extracellular microenvironment to compete for implantation sites and inhibit peritoneal metastasis, which has been validated in relevant models.

    Journal: International Journal of Nanomedicine

    Article Title: Exosomes in Ovarian Cancer: Promoters, Biomarkers, and Therapeutic Targets

    doi: 10.2147/IJN.S606735

    Figure Lengend Snippet: ( a ) Activated immune cells: TLR3 agonists reverse tumor-induced immune tolerance. Cell-free vaccines composed of tumor-derived exosomes can elicit robust and durable tumor antigen-specific T cell responses. Exosome-mimicking liposomal formulations carrying miR-155-5p, as well as engineered hexamer ExoBlock with six high-affinity PS-binding sites, can activate CD8⁺ T cells, promote Treg proliferation and upregulate PD-L1, thereby markedly improving the efficacy of checkpoint blockade therapy. ( b ) Chemoresistance sensitization: miR497/TP-HENPs, hybrid nanoparticles integrating liposomes and exosomes and co-loaded with TP and miR497, specifically block the PI3K/AKT/mTOR pathway and effectively reverse chemoresistance in ovarian cancer. Dendritic cell-derived exosomes expressing RGD-Lamp2b fusion proteins can deliver miR-484 in a targeted manner to normalize tumor vasculature and sensitize cancer cells to chemotherapy. ( c ) Engineered exosomes: Exosomes loaded with mangiferin and curcumin, as well as exosomes electroporated with plasmids encoding Cas9 and PARP-1 sgRNA, efficiently induce apoptosis in ovarian cancer cells. Exosomes carrying ephrin-B2 ligands bind to LAMP-2b and target ephrin-B4 on ovarian cancer cell surfaces, which greatly reduces systemic toxicities. RGD-modified exosomes possess enhanced cellular penetration ability. Their highly expressed miR-92b-3p targets SOX4 to suppress tumor growth and angiogenesis; combined with apatinib, they exert a potent synergistic anti-tumor effect via anti-angiogenesis. M-Trap is an exosome-based tumor capture technology that immobilizes exosomes purified from ascites of ovarian cancer patients onto 3D polystyrene/polycaprolactone scaffolds. It mimics the extracellular microenvironment to compete for implantation sites and inhibit peritoneal metastasis, which has been validated in relevant models.

    Article Snippet: Exosome-based therapy represents a breakthrough in nanomedicine, particularly in personalized medicine and cancer treatment.

    Techniques: Vaccines, Derivative Assay, Binding Assay, Liposomes, Blocking Assay, Expressing, Modification, Purification